English Polski
Vol 13, No 3 (2020)
Guidelines / Expert consensus
Published online: 2020-12-03

open access

Page views 857
Article views/downloads 1029
Get Citation

Connect on Social Media

Connect on Social Media

Emicizumab (Hemlibra®) in hemophilia A patients with inhibitors against factor VIII — guidelines of the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine

Jerzy Windyga1, Krzysztof Chojnowski2, Anna Klukowska3, Paweł Łaguna3, Magdalena Łętowska4, Andrzej Mital5, Wojciech Młynarski6, Jacek Musiał7, Jacek Treliński8, Anetta Undas9, Tomasz Urasiński10, Joanna Zdziarska11, Maria Podolak-Dawidziak12
Journal of Transfusion Medicine 2020;13(3):165-175.

Abstract

In this document, the Group for Haemostasis of the Polish Society of Haematology and Transfusion Medicine presents the guidelines for the use of emicizumab. Emicizumab (Hemlibra®, F. Hoffmann — La Roche, Basel, Switzerland) has been licensed for use in the European Union in 2018. In Poland, this medicinal product has been available for patients with congenital hemophilia A and inhibitors against factor VIII since March 2020. This paper is a supplement to the 2017 guidelines for management of patients with haemophilia A and B and inhibitors against factor VIII or IX.

Article available in PDF format

View PDF Download PDF file